Welzel, T. M., Petersen, J., Herzer, K., Ferenci, P., Gschwantler, M., Wedemeyer, H., . . . Zeuzem, S. (2016). Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut.
Citação norma ChicagoWelzel, Tania M., et al. "Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, Achieved High Sustained Virological Response Rates in Patients With HCV Infection and Advanced Liver Disease in a Real-world Cohort." Gut 2016.
ציטוט MLAWelzel, Tania M., et al. "Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, Achieved High Sustained Virological Response Rates in Patients With HCV Infection and Advanced Liver Disease in a Real-world Cohort." Gut 2016.